Quarterly report pursuant to Section 13 or 15(d)

Corporate Collaborations (Details)

v2.4.0.8
Corporate Collaborations (Details) (USD $)
1 Months Ended 1 Months Ended 3 Months Ended 0 Months Ended
Jun. 30, 2014
Collaborative Arrangement [Member]
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Development Events [Member]
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Regulatory Events [Member]
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Product Launch Events [Member]
Aug. 31, 2002
Daiichi Sankyo [Member]
Jun. 30, 2014
Daiichi Sankyo [Member]
Apr. 30, 2013
Daiichi Sankyo [Member]
Milestone Achievement Group One [Member]
Jan. 31, 2012
Daiichi Sankyo [Member]
Milestone Achievement Group One [Member]
Jul. 31, 2012
BerGenBio AS Worldwide License Agreement [Member]
Jul. 31, 2012
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
Jun. 30, 2012
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
Dec. 31, 2013
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
Specified Development Events [Member]
Collaborations                        
Maximum amount of contingent payments receivable $ 152,300,000 $ 61,200,000 $ 53,600,000 $ 37,500,000                
Upfront fee received                   1,000,000    
Revenue recognized                     1,000,000 5,800,000
Collaborative payment received             1,400,000 750,000 500,000      
Cumulative amount of payments earned under collaborative arrangement           $ 7,900,000            
Period of collaboration in research phase         3 years